查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951290

皮膚科藥物市場－全球產業規模、佔有率、趨勢、機會和預測：治療方法、類型、給藥途徑、藥物類別、分銷管道、地區和競爭格局分類，2021-2031年

Dermatological Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Type, By Route of Administration, By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球皮膚病藥物市場預計將從 2025 年的 220.2 億美元成長到 2031 年的 385.2 億美元，複合年成長率為 9.77%。

此細分市場包括用於診斷和治療皮膚、毛髮和指甲疾病的藥物製劑，涵蓋外用、口服和注射。市場成長的主要促進因素是慢性皮膚病（如乾癬和異位性皮膚炎）發病率的上升，以及人口老化導致老年人更容易患皮膚病。例如，美國國家濕疹協會報告稱，到2025年，超過10%的美國人口將被診斷出患有某種形式的濕疹，這凸顯了有效治療性介入的重要性以及全球市場的擴張趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 220.2億美元
市場規模：2031年 385.2億美元
複合年成長率：2026-2031年 9.77%
成長最快的細分市場 處方箋
最大的市場 北美洲

儘管前景樂觀，但由於先進生物療法和新型小分子藥物的高成本，市場仍面臨許多障礙。高昂的價格往往導致患者難以獲得治療和報銷，尤其是在醫療預算緊張的發展中地區。此外，新化學實體藥物嚴格的監管核准通訊協定可能會延遲其上市時間並增加研發成本。因此，這些財務和監管障礙可能會阻礙創新治療方法的廣泛應用，並對整個產業的擴張構成嚴重阻礙。

市場促進因素

全球慢性及急性皮膚病患病率的不斷上升是推動市場成長的主要因素，也因此需要更多藥物介入。從自體免疫疾病到皮膚惡性腫瘤，各種疾病的診斷率不斷攀升，迫使醫療系統優先考慮有效治療方法。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》，預計當年美國將新增100,640例侵襲性黑色素瘤病例。日益加重的疾病負擔與腫瘤相關皮膚科藥物處方量的增加直接相關，從而推動了對創新治療方法的持續需求，以有效滿足患者的複雜需求。

同時，生物製藥、小分子藥物和標靶治療的進步，憑藉其優於傳統全身性治療的療效和安全性，正在重塑市場競爭格局。製藥公司正積極拓展產品組合，開發具有全新作用機制的藥物，尤其針對異位性皮膚炎等難治性疾病。根據賽諾菲於2024年2月發布的“2023會計年度全年業績報告”，其用於治療異位性皮膚炎的生物製藥Dupixent的銷售額達到107.6億歐元，這主要得益於患者需求的強勁成長。此外，美容領域的成長也為該行業提供了支撐。艾伯維在2024年發布的預測顯示，其2023會計年度肉毒桿菌素（Botox Cosmetic）的全球淨銷售額將達到26.8億美元，這證實了美容皮膚科是整體市場估值的重要組成部分。

市場挑戰

先進生物製藥和新型小分子藥物的高昂成本對全球皮膚病藥物市場的擴張構成重大挑戰。這些創新治療方法的巨額價格往往超出醫療預算的承受能力，迫使支付方實施嚴格的報銷限制，例如階梯療法和事先核准。這些成本控制措施嚴重阻礙了患者獲得治療，導致很大一部分合格的患者無法獲得處方治療。缺乏健保覆蓋減緩了這些高價值藥物的普及速度，直接限制了生產商的收入成長，並阻礙了整個產業的財務發展。

近期產業數據顯示，生物製藥處方箋保險公司延遲或拒付。如此高的拒付率嚴重限制了先進療法的市場滲透率。因此，市場無法有效地將這些昂貴但有效的藥物提供給患者，這嚴重阻礙了整個產業的成長。

市場趨勢

人工智慧的融合正在從根本上改變皮膚病學領域的藥物研發格局。製藥公司正積極利用生成式人工智慧模型來識別藥物標靶並最佳化分子設計，從而顯著縮短新治療方法商業化所需的時間和資金投入。這種技術變革對於複雜的皮膚疾病尤其重要，因為傳統的篩檢方法難以找到有效的候選藥物。例如，在2024年1月題為「Almirall宣布與微軟建立合作夥伴關係」的新聞稿中，Almirall宣布了一項為期三年的策略合作，該合作將充分利用生成式人工智慧和先進的分析技術，加速醫學皮膚病學領域創新治療方法的發現和開發。

同時， Janus激酶（JAK）抑制劑正迅速崛起，成為治療免疫介導性皮膚疾病（如白斑和異位性皮膚炎）領域亟待解決的重大治療層級。與廣譜免疫抑制劑不同，這些小分子藥物針對細胞激素通路，對可能對生物製藥無反應的患者俱有高效療效。這些藥物的商業性成功表明，它們正日益被尋求非類固醇替代療法治療慢性疾病的醫生和患者所接受。根據Incyte公司於2024年10月發布的“2024年第三季財務業績”，外用JAK抑制劑Opzelula的淨產品銷售額在第三季度達到1.39億美元，同比成長52%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球皮膚科藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療類型（痤瘡、乾癬、酒糟、脫髮症、其他）
    • 依類型（處方藥、非處方藥）
    • 依給藥途徑（局部用藥、口服、注射）
    • 依藥物類別（皮質類固醇、類視色素、抗生素、抗真菌藥物、Calcineurin抑制劑、其他）
    • 按分銷管道（醫院藥房、零售藥房、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美皮膚科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲皮膚科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區皮膚科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲皮膚科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲皮膚科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球皮膚科藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Pfizer Inc.
  • Glaxo Smith Kline PLC
  • Sun Pharmaceutical Industries Ltd
  • Galderma SA
  • Amgen Inc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Almirall, SA
  • Eli Lilly and Company
  • Bausch Health Companies Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17585

The Global Dermatological Drugs Market is projected to expand from USD 22.02 billion in 2025 to USD 38.52 billion by 2031, reflecting a compound annual growth rate of 9.77%. This sector comprises pharmaceutical formulations, including topical, oral, and parenteral therapies, developed to diagnose and manage conditions affecting the skin, hair, and nails. The market's growth is largely driven by the rising incidence of chronic skin diseases, such as psoriasis and atopic dermatitis, along with an aging demographic prone to dermatological issues. For instance, the National Eczema Association reported in 2025 that over 10% of the United States population had been diagnosed with some form of eczema, highlighting the critical need for effective therapeutic interventions and the broadening scope of the global market.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 22.02 Billion
Market Size 2031USD 38.52 Billion
CAGR 2026-20319.77%
Fastest Growing SegmentPrescription
Largest MarketNorth America

Despite this positive outlook, the market faces significant hurdles due to the high costs associated with advanced biologic therapies and novel small molecule drugs. These premium pricing structures often lead to restricted patient access and reimbursement limitations, particularly in developing regions with tighter healthcare budgets. Additionally, rigorous regulatory approval protocols for new chemical entities can prolong market entry and escalate development expenses. Consequently, these financial and regulatory barriers pose serious obstacles that could hinder the widespread adoption of innovative treatments and slow the sector's overall expansion.

Market Driver

The increasing global prevalence of both chronic and acute skin disorders acts as a primary catalyst for market growth, requiring a greater volume of pharmaceutical interventions. With diagnosis rates climbing for conditions ranging from autoimmune diseases to skin malignancies, healthcare systems are compelled to prioritize effective therapeutics. According to the American Cancer Society's "Cancer Facts & Figures 2024," released in January 2024, an estimated 100,640 new cases of invasive melanoma were projected to be diagnosed in the United States within that year. This rising disease burden directly leads to higher prescription volumes for oncology-related dermatological drugs and drives the persistent need for innovative treatment modalities to handle complex patient requirements effectively.

Simultaneously, the competitive landscape is being reshaped by advancements in biologics, small molecules, and targeted therapies, which offer superior efficacy and safety compared to traditional systemic treatments. Pharmaceutical companies are actively broadening their portfolios with novel mechanisms of action, especially for refractory conditions like atopic dermatitis. As reported by Sanofi in February 2024 within their "Full Year 2023 Results," sales of Dupixent, a biologic for atopic dermatitis, reached €10.76 billion due to strong patient demand. Furthermore, the sector is supported by the thriving aesthetic segment; according to AbbVie in 2024, global net revenues for Botox Cosmetic totaled $2.68 billion for the full year 2023, confirming the significant economic contribution of cosmetic dermatology to the total market valuation.

Market Challenge

The substantial cost associated with advanced biologic therapies and novel small molecule drugs constitutes a major challenge hindering the expansion of the Global Dermatological Drugs Market. The premium pricing of these innovative treatments often exceeds the financial capacity of healthcare budgets, forcing payers to implement strict reimbursement restrictions such as step therapy and prior authorization. These cost-containment measures create significant barriers to patient access, effectively preventing a large segment of the eligible population from obtaining prescribed treatments. When coverage is unobtainable, the adoption rate of these high-value drugs slows, which directly limits revenue growth for manufacturers and stalls the sector's financial progress.

This trend of restricted accessibility is confirmed by recent industry data emphasizing the severity of coverage obstacles. In 2024, the National Eczema Association cited a study revealing that 44% of prescriptions for biologic therapies were either delayed or denied by insurers due to stringent coverage protocols. Such elevated denial rates significantly limit the market penetration of advanced formulations. Consequently, the market's inability to efficiently deliver these expensive but effective drugs to patients functions as a critical brake on the overall industry's trajectory.

Market Trends

The integration of artificial intelligence is fundamentally transforming the drug discovery landscape within the dermatological sector. Pharmaceutical companies are increasingly utilizing generative AI models to identify new therapeutic targets and optimize molecule design, thereby significantly reducing the time and capital required to bring new treatments to market. This technological shift is particularly vital for complex skin conditions where traditional screening methods have historically struggled to identify effective candidates. For instance, Almirall announced in a January 2024 press release titled "Almirall Announces Partnership With Microsoft" that it had established a three-year strategic collaboration to deploy generative AI and advanced analytics specifically to accelerate the discovery and development of innovative therapies for medical dermatology.

Concurrently, Janus kinase (JAK) inhibitors are rapidly emerging as a dominant therapeutic class, addressing significant unmet needs in immune-mediated skin diseases such as vitiligo and atopic dermatitis. Unlike broad-spectrum immunosuppressants, these small molecule therapies offer targeted modulation of cytokine pathways, providing high efficacy for patients who may not respond to conventional biologics. The commercial success of these formulations highlights their growing acceptance among prescribers and patients seeking non-steroidal alternatives for chronic conditions. According to Incyte's "2024 Third Quarter Financial Results" from October 2024, net product revenues for Opzelura, a topical JAK inhibitor, reached $139 million for the third quarter, marking a substantial 52% increase compared to the same period in the previous year.

Key Market Players

  • AbbVie Inc.
  • Pfizer Inc.
  • Glaxo Smith Kline PLC
  • Sun Pharmaceutical Industries Ltd
  • Galderma SA
  • Amgen Inc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Almirall, S.A
  • Eli Lilly and Company
  • Bausch Health Companies Inc.

Report Scope

In this report, the Global Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Drugs Market, By Therapy

  • Acne
  • Psoriasis
  • Rosacea
  • Alopecia
  • Others

Dermatological Drugs Market, By Type

  • Prescription
  • Over-the-counter

Dermatological Drugs Market, By Route of Administration

  • Topical
  • Oral
  • Parenteral

Dermatological Drugs Market, By Drug Class

  • Corticosteroids
  • Retinoids
  • Antibiotics
  • Antifungals
  • Calcineurin Inhibitors
  • Others

Dermatological Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Dermatological Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Drugs Market.

Available Customizations:

Global Dermatological Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermatological Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Acne, Psoriasis, Rosacea, Alopecia, Others)
    • 5.2.2. By Type (Prescription, Over-the-counter)
    • 5.2.3. By Route of Administration (Topical, Oral, Parenteral)
    • 5.2.4. By Drug Class (Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Dermatological Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Drug Class
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dermatological Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Drug Class
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Dermatological Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Drug Class
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Dermatological Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Drug Class
        • 6.3.3.2.5. By Distribution Channel

7. Europe Dermatological Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Drug Class
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dermatological Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Drug Class
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. France Dermatological Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Drug Class
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Dermatological Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Drug Class
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Dermatological Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Drug Class
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Dermatological Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Drug Class
        • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Dermatological Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Drug Class
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dermatological Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Drug Class
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Dermatological Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Drug Class
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Dermatological Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Drug Class
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Dermatological Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Drug Class
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Dermatological Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Drug Class
        • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Dermatological Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Drug Class
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dermatological Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Drug Class
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. UAE Dermatological Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Drug Class
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. South Africa Dermatological Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Drug Class
        • 9.3.3.2.5. By Distribution Channel

10. South America Dermatological Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Drug Class
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dermatological Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Drug Class
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Colombia Dermatological Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Drug Class
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Argentina Dermatological Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Drug Class
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dermatological Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Glaxo Smith Kline PLC
  • 15.4. Sun Pharmaceutical Industries Ltd
  • 15.5. Galderma SA
  • 15.6. Amgen Inc
  • 15.7. Johnson & Johnson Services, Inc.
  • 15.8. Novartis AG
  • 15.9. Almirall, S.A
  • 15.10. Eli Lilly and Company
  • 15.11. Bausch Health Companies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer